JNJ250502P139000
- 0.01
- 0.000.00%
Johnson & Johnson Newsroom
Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Goldman Sachs Adjusts Price Target on Johnson & Johnson to $176 From $172, Maintains Buy Rating
SA Charts: How U.S. Manufacturing Jobs Have Declined Since the 1980s
Express News | Jnj-Backed Histosonics Is Pursuing a Sale After Fielding Takeover Bids, Seeking a Valuation of More Than $2.5Bn - FT
8 Health Care Stocks Whale Activity In Today's Session
Johnson & Johnson (JNJ.US) has received FDA approval for a potential blockbuster therapy.
Zhitong Finance APP learned that Johnson & Johnson (JNJ.US) announced that the USA FDA has approved the market launch of its antibody therapy Imaavy (nipocalimab).
On April 30, the top 20 trading volumes in the U.S. stock market: Super Micro Computer's preliminary Earnings Reports significantly missed expectations.
On Wednesday, Tesla, ranked first in U.S. stock trading volume, closed down 3.38% with a transaction volume of 35.226 billion USD. Data shows that as of the week ending April 27, the number of new registered Tesla electric vehicles in the domestic market was 10,300, a 51% increase from the previous week's 6,780, but down 30.5% compared to the same period last year. NVIDIA, ranked second, closed down 0.09% with a transaction volume of 23.471 billion USD. Super Micro Computer, a manufacturer of AI servers, provided a performance forecast that was far below expectations, raising concerns among investors about weak demand for AI servers, which dragged down stocks like NVIDIA. Meta ranked third.
Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?
Express News | J&J Says Wholesale Acquistion Cost or U.S. List Price of Immune Disorder Drug Imaavy Is $12,480 for 1200Mg Vial
Option Care Health Upgraded at UBS on Valuation After Q1 Beat
Johnson & Johnson Gets US FDA Approval for Imaavy
Johnson & Johnson Receives FDA Approval For IMAAVYTM, A New FcRn Blocker Offering Long-Lasting Disease Control In The Broadest Population Of People Living With Generalized Myasthenia Gravis
Express News | Johnson & Johnson Receives FDA Approval for Imaavytm (Nipocalimab-Aahu), a New Fcrn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (Gmg)
Honeywell, Sherwin-Williams Co. Share Gains Lead Dow's 232-Point Jump
Johnson & Johnson (JNJ): Among the Best Long-Term Dividend Stocks to Buy According to Billionaires
Barclays Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $165
Nvidia, Johnson & Johnson, Hyundai, Toyota, SoftBank CEOs To Join Trump At White House As He Touts Investment Surge In First 100 Days: Report
On the occasion of his first hundred days in office, Trump will hold an event at the White House to promote investment in the USA, with Company Executives from NVIDIA and other companies participating.
US government officials stated that on the 100th day of Trump's second term, over 20 senior business leaders from companies such as NVIDIA, Johnson & Johnson, Toyota, Eli Lilly and Co, and SoftBank Group will visit the White House on Wednesday to participate in an event promoting investment in the USA. A White House official mentioned that Trump plans to advocate for and promote widespread investment in the fields of USA defense, Technology, Medical Care, Consumer products, and investment Funds on the occasion of his hundredth day in office. Despite the concerns of major US enterprises regarding new tariffs, Trump is still trying to attract new investments. Airlines, aerospace companies, Auto Manufacturers, and retailers are all concerned about the impact of tariffs on USA manufacturing.
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $170